Top Markets
Coin of the day
Reviva Pharmaceuticals Holdings, Inc. Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc.

RVPHW
株式のランク #39803
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical... Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for diseases with substantial unmet medical needs. Their pipeline targets disorders within the central nervous system, respiratory, cardiovascular, metabolic, and inflammatory disease categories. The company's leading drug candidate, brilaroxazine (RP5063), is currently in Phase III clinical trials for the treatment of schizophrenia. This compound has also completed Phase I trials for a diverse set of conditions, including bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, the behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Furthermore, Reviva is advancing RP1208, which is in pre-clinical development for depression and obesity. Founded in 2018, the company is headquartered in Cupertino, California.
株価
$0.003
最終同期: 2025-12-12
時価総額
$343.91K
変化(1日)
-16.67%
変化(1年)
-90.23%
US
取引 Reviva Pharmaceuticals Holdings, Inc. (RVPHW)

カテゴリー

Reviva Pharmaceuticals Holdings, Inc.(RVPHW)の利益
2026 時点の利益 TTM: 0
Reviva Pharmaceuticals Holdings, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Reviva Pharmaceuticals Holdings, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益